FDA panel unanimously backs biosimilar Zarxio

FDA's Oncologic Drugs Advisory Committee voted 14-0 to recommend approval of Zarxio ( EP2006) G-CSF from the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN), a biosimilar of neutropenia drug Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN). The panel recommended

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE